No connection

Search Results

ABBV vs ATHE

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ATHE
Alterity Therapeutics Limited
BEARISH
Price
$3.55
Market Cap
$64.3M
Sector
Healthcare
AI Confidence
65%

Valuation

P/E Ratio
ABBV
163.63
ATHE
--
Forward P/E
ABBV
15.42
ATHE
-4.49
P/B Ratio
ABBV
-146.66
ATHE
1038.03
P/S Ratio
ABBV
6.5
ATHE
11.83
EV/EBITDA
ABBV
15.27
ATHE
-2231.26

Profitability

Gross Margin
ABBV
71.46%
ATHE
97.66%
Operating Margin
ABBV
35.5%
ATHE
-185.73%
Profit Margin
ABBV
4.0%
ATHE
-223.35%
ROE
ABBV
137.96%
ATHE
-43.23%
ROA
ABBV
9.59%
ATHE
-28.09%

Growth

Revenue Growth
ABBV
9.1%
ATHE
80.9%
Earnings Growth
ABBV
-88.7%
ATHE
--

Financial Health

Debt/Equity
ABBV
--
ATHE
0.0
Current Ratio
ABBV
0.72
ATHE
12.98
Quick Ratio
ABBV
0.47
ATHE
12.62

Dividends

Dividend Yield
ABBV
3.05%
ATHE
--
Payout Ratio
ABBV
490.15%
ATHE
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ATHE BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score limits bankruptcy risk assessment. Despite strong revenue growth of 80.90% YoY and a pristine balance sheet with zero debt and a current ratio of 12.98, the company is deeply unprofitable with a profit margin of -223.35% and negative ROE of -43.23%. Valuation metrics are extreme, with a Price/Book of 1038.03 and a negative Forward P/E of -4.49, suggesting significant overvaluation relative to book and earnings. While insider sentiment is moderately positive at 40/100 and analysts project a high target price of $12.00, the lack of profitability, inconsistent cash flow data, and weak technical trend (0/100) raise serious concerns about sustainability.

Strengths
Exceptional revenue growth of 80.90% YoY, significantly above sector average of 23.74%
Zero debt with a Debt/Equity ratio of 0.00, indicating strong capital structure flexibility
Very high liquidity with Current Ratio of 12.98 and Quick Ratio of 12.62
Risks
Piotroski F-Score of 4/9 indicates weak financial health and limited profitability strength
Extremely high valuation: Price/Book of 1038.03 and negative Forward P/E suggest severe overvaluation
Deeply negative profitability: Profit margin of -223.35% and ROE of -43.23% signal ongoing losses

Compare Another Pair

ABBV vs ATHE: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Alterity Therapeutics Limited (ATHE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile